{
}
The High Potency Active Pharmaceutical Ingredients Market is experiencing significant growth, driven by increased demand, technological advancements, and a broadening customer base. A comprehensive report provides insights into market trends, competitive landscape, and future opportunities, highlighting key players such as Lonza and Novartis. The analysis covers various segments, production technologies, and applications, offering a detailed outlook on the industry's trajectory through 2032.
Eli Lilly is poised for increased Q1 sales of Zepbound, as indicated by UBS. The company's net sales are primarily driven by endocrinology (65.5%), followed by oncology (19.4%), immunological diseases (9.8%), neurology (3.3%), and other areas (2%). Geographically, 67.4% of sales come from the United States, with Europe at 15.4%, Japan at 4%, China at 3.7%, and other regions at 9.5%.
Eli Lilly and Company, a leading pharmaceutical group, is expected to see an increase in Zepbound sales in Q1, according to UBS. The company's sales are primarily driven by endocrinology (65.5%), followed by oncology (19.4%), immune diseases (9.8%), neurology (3.3%), and other areas (2%). Geographically, 67.4% of sales come from the United States, with Europe at 15.4%, Japan at 4%, China at 3.7%, and other regions at 9.5%.
UBS has maintained a Neutral rating on Eli Lilly (NYSE: LLY) with a price target of $1,100, noting a recent uptick in prescriptions for Zepbound despite previous product performance setbacks. The company has seen a 32% revenue growth over the past year, with expectations for Zepbound adjusted upward by 2%. Looking ahead, the anticipated release of orfo diabetes data in Q2 2025 could significantly boost investor interest, with a 70% probability of success for the ACHIEVE-1 study.
UBS has maintained a "Neutral" rating on Eli Lilly (NYSE: LLY) with a price target of $1,100, noting the company's strong revenue growth despite recent product performance setbacks. The upcoming release of Orfo diabetes data in Q2 2025 is highly anticipated, with a 70% probability of success for the ACHIEVE-1 trial, which could enhance investor interest. Eli Lilly's recent launch of Mounjaro in India positions it competitively in a market facing rising obesity and diabetes rates.
UBS has reaffirmed its Buy rating on Eli Lilly, setting a price target of $1,100 as the stock trades at $847.24. The company has shown strong sales growth, particularly for its Zepbound product, despite recent challenges with Mounjaro. Anticipation builds for the upcoming ACHIEVE-1 study on oral diabetes treatment, which could significantly impact investor sentiment.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted that rival Eli Lilly's weight-loss injection, Zepbound, has seen a stronger recovery in prescriptions compared to Novo's Wegovy following the Christmas period.
Eli Lilly has announced a $2.5 billion acquisition of Scorpion Therapeutics’ PI3Kα pipeline, aiming to compete in the breast cancer market against Novartis and Roche. The deal includes the promising candidate STX-478, which has shown a 23% response rate in patients and is designed to selectively target mutant PI3Kα, potentially avoiding adverse effects seen with existing treatments. Lilly will also create a new company for Scorpion's non-PI3Kα assets, retaining Scorpion's staff.
The global cancer immunotherapy market is projected to reach $135.2 billion in 2024, growing at a CAGR of 9.8% to $236.9 billion by 2030, driven by rising cancer prevalence and demand for effective treatments. North America leads the market, while Asia-Pacific is the fastest-growing region. Monoclonal antibodies dominate the product segment, with lung cancer applications holding the largest market share, and breast cancer expected to grow the fastest.
The semaglutides market is projected to grow from $20.54 billion in 2023 to $36.87 billion by 2028, driven by rising diabetes prevalence and increased demand for effective treatments. Key players are innovating with GLP-1 receptor analogues and oral formulations to enhance patient adherence and reduce side effects. North America leads the market, while Asia-Pacific is expected to be the fastest-growing region.
Eli Lilly and Company
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
high potency active pharmaceutical ingredients market trends and future growth prospects
Merck & Co., Inc.
Roche Diagnostics AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd
BASF AG
Novartis International AG
Lonza Group AG
Bristol-Myers Squibb Co
Cambrex Corporation
Seqens
Pfizer Inc.
Sanofi Aventis SA
Bayer AG
CARBOGEN AMCIS AG
Alice Mutum
Viju Shah
Show more
10:02 26.03.2025
eli lilly anticipates increased zepbound sales in first quarter
15:53 24.03.2025
eli lilly anticipates zepbound sales growth in first quarter
15:53 24.03.2025
ubs maintains neutral rating on eli lilly with 1100 price target
15:33 24.03.2025
ubs maintains neutral rating on eli lilly with price target of 1100
15:26 24.03.2025
ubs maintains buy rating on eli lilly with strong sales growth prospects
14:52 24.03.2025
ubs maintains buy rating for novo nordisk with target price of 750 crowns
08:15 21.01.2025
eli lilly acquires scorpion therapeutics for 2.5 billion in breast cancer push
Novartis International AG
Roche Holding AG
Eli Lilly and Company
Relay Therapeutics, Inc.
USA
Daniel M. Skovronsky
Show more
15:55 13.01.2025
global cancer immunotherapy market projected to reach 236.9 billion by 2030
United States Dollar
GSK plc
Bristol-Myers Squibb Company
Bayer AG
Eli Lilly and Company
Pfizer Inc.
Merck & Co., Inc.
Novartis AG
Immunocore Holdings plc
AstraZeneca PLC
Amgen Inc.
F. Hoffmann-La Roche Ltd.
IND
FRA
ARG
CAN
ESP
USA
BRA
CHN
MEX
DEU
ITA
JPN
GBR
KOR
Show more
10:06 10.01.2025
semaglutides market projected to reach 36.87 billion by 2028
United States Dollar
Adocia SA
Sanofi SA
Eli Lilly and Company
Roche Holding AG
Pfizer Inc.
Merck & Co., Inc.
Dr. Reddy's Laboratories Limited
Boehringer Ingelheim International GmbH
Glaxosmithkline plc
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Novartis International AG
Bristol-Myers Squibb Company
Novo Nordisk A/S
Cipla Limited
Biocon Limited
Teva Pharmaceutical Industries Ltd
AstraZeneca PLC
Amgen Inc.
ITA
IND
FRA
IDN
CAN
ESP
BRA
USA
RUS
CHN
DEU
AUS
JPN
GBR
KOR
Show more
10:12 06.01.2025
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
Domestic Politics
Banking Regulations
Global Financial Events
CEO Changes
Government Policies
Retail and Consumer Goods
Workplace Trends
Elections & Campaigns
Market Analysis and Predictions
Central Bank Actions
Global Trade Developments
Startups & Entrepreneurship
Hedge Funds & Private Equity
Banking & Investment Regulations
Corporate Social Responsibility
Countries:
Companies:
Tesla, Inc.
UniCredit S.p.A.
Banco BPM S.p.A.
Deutsche Bank Money Market PP
JPMorgan Chase & Co.
Barclays PLC
Credit Suisse Strategic Income I
Apple Inc.
CREDIT AGRICOLE
SpaceXCoin USD
Lloyds Banking Group plc
BNP Paribas SA
Amazon.com, Inc.
The Goldman Sachs Group, Inc.
UBS Group AG
Credit Agricole
Banco Santander, S.A.
Reinsurance Group of America, Incorporated
Amundi S.A.
Commerzbank AG
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Offshore Chinese Yuan
Hong Kong Dollar
Norwegian Krone
Filipino Peso
Canadian Dollar
Singapore Dollar
Australian Dollar
Danish Krone
Swedish Krona
Mexican Peso
Qatari Riyal
South African Rand
People: